Bone Biologics Corp Quarterly Earnings Per Share, Diluted in USD/shares from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Bone Biologics Corp quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2016 to Q3 2024.
  • Bone Biologics Corp Earnings Per Share, Diluted for the quarter ending September 30, 2024 was -2.37 USD/shares, a 51.6% increase year-over-year.
  • Bone Biologics Corp Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was 28.3 USD/shares.
  • Bone Biologics Corp annual Earnings Per Share, Diluted for 2023 was -34 USD/shares, a 9.18% decline from 2022.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $28.30 -$2 +$2.53 +51.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $25.80 $0.67 +$5.88 Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $19.90 -$1 +$53.90 +97.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$34 $31.30 Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 -$5 -$1 -38.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$5 -$4 -283% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$55 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q3 2022 -$4 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$1 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q2 2018 $0 -$1 -216% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-14
Q2 2017 $0.25 +$0.38 Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.